Edition:
United Kingdom

Biomarin Announces Full Year And Fourth Quarter 2018 Results


Thursday, 21 Feb 2019 

Feb 21 (Reuters) - Biomarin Pharmaceutical Inc ::BIOMARIN ANNOUNCES FULL YEAR AND FOURTH QUARTER 2018 RESULTS.QTRLY LOSS PER SHARE $0.03.QTRLY TOTAL REVENUES $353.2 MILLION VERSUS $358.3 MILLION.Q4 EARNINGS PER SHARE VIEW $-0.25, REVENUE VIEW $377.1 MILLION -- REFINITIV IBES DATA.GLOBAL PHASE 3 VOSORITIDE STUDY IN CHILDREN WITH ACHONDROPLASIA ENROLLMENT COMPLETE WITH DATA EXPECTED BY YEAR-END 2019.IN EUROPE, CHMP OPINION FOR PALYNZIQ ANTICIPATED IN Q1 2019.ENROLLMENT COMPLETE FOR ACCELERATED FILING REQUIREMENTS FOR VALOCTOCOGENE ROXAPARVOVEC FOR HEMOPHILIA A.SEES 2019 TOTAL REVENUES $1,680 TO $1,750 MILLION.FY2019 REVENUE VIEW $1.73 BILLION -- REFINITIV IBES DATA.SEES 2019 NON-GAAP INCOME $130 TO $170 MILLION.